Table 2.
Demographic Characteristics of the Study Subjects According to Quartiles of Total AAAs
| Characteristics | Q1 (80) | Q2 (81) | Q3 (81) | Q4 (80) | P-value |
|---|---|---|---|---|---|
| Age (year)* | 70(66, 76) | 69(66, 74) | 67(64, 73) | 67(64, 71) | 0.013 |
| Height (cm) | 157.3 ± 8.0 | 157.5 ± 7.7 | 160.4 ± 7.9 | 163.2 ± 9.0 | <0.001 |
| Weight (kg) | 62.6 ± 10.5 | 62.8 ± 10.4 | 64.8 ± 11.0 | 70.4 ± 11.6 | <0.001 |
| Urine volume* | 925(700, 1200) | 900(700, 1500) | 1150(690, 1550) | 1355(1000, 1750) | <0.001 |
| Gender (female) | 51 (63.8%) | 45 (55.6%) | 37 (45.7%) | 27 (33.8%) | 0.001 |
| Smoking history | 15 (18.8%) | 17 (21.0%) | 26 (32.1%) | 21 (26.3%) | 0.201 |
| Current smoking habit | 6 (7.5%) | 9 (11.1%) | 12 (14.8%) | 12 (15.0%) | 0.414 |
| Education (primary) | 78 (97.5%) | 79 (97.5%) | 76 (93.8%) | 71 (88.8%) | 0.057 |
| Drugs history | |||||
| Diuretics | 19 (23.8%) | 10 (12.3%) | 9 (11.1%) | 11 (13.8%) | 0.101 |
| ACEI | 25 (31.3%) | 30 (37.0%) | 29 (35.8%) | 32 (40.0%) | 0.711 |
| α-receptor blockers | 5 (6.3%) | 3 (3.7%) | 2 (2.5%) | 4 (5.0%) | 0.662 |
| β-receptor blockers | 9 (11.3%) | 6 (7.4%) | 15 (18.5%) | 9 (11.3%) | 0.178 |
| Calcium antagonists | 41 (51.3%) | 50 (61.7%) | 47 (58.0%) | 51 (63.8%) | 0.392 |
| Other antihypertensives | 17 (21.3%) | 11 (13.6%) | 11 (13.6%) | 8 (10.0%) | 0.228 |
| Lipid-lowering drugs | 6 (7.5%) | 4 (4.9%) | 3 (3.7%) | 4 (5.0%) | 0.758 |
| Antiplatelet agents | 23 (38.8%) | 23 (28.4%) | 14 (17.3%) | 24 (30.0%) | 0.221 |
Note: *Values shown are Median (P25, P75).
Abbreviations: ACEI, angiotensin conversion enzyme inhibitors; total AAAs, tyrosine + phenylalanine + tryptophan; Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile.